SGLT-2 inhibition - with its positive effects on energy metabolism and mitochondrial function, negative modulation of proinflammatory mediators, and reduction of fibrillar collagen deposition - could therefore modify atrial remodeling and the development of the arrhythmia [2]. The gene discussed is SLC5A2; the disease is cardiac arrhythmia.